Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
Cheah CY, Bröckelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA. Cheah CY, et al. Among authors: bartlett nl. Am J Hematol. 2016 Sep;91(9):894-9. doi: 10.1002/ajh.24429. Epub 2016 Jun 20. Am J Hematol. 2016. PMID: 27222367 Free article.
New therapies in Hodgkin's lymphoma.
Bartlett N. Bartlett N. Clin Adv Hematol Oncol. 2004 Feb;2(2):80, 83. Clin Adv Hematol Oncol. 2004. PMID: 16163165 No abstract available.
Modern treatment of Hodgkin lymphoma.
Bartlett NL. Bartlett NL. Curr Opin Hematol. 2008 Jul;15(4):408-14. doi: 10.1097/MOH.0b013e328302c9d8. Curr Opin Hematol. 2008. PMID: 18536581 Review.
Salvage regimens for Hodgkin lymphoma.
Cashen AF, Bartlett NL. Cashen AF, et al. Among authors: bartlett nl. Clin Adv Hematol Oncol. 2008 Jul;6(7):517-24. Clin Adv Hematol Oncol. 2008. PMID: 18654119 Review.
The present: optimizing therapy--too much or too little?
Bartlett NL. Bartlett NL. Hematology Am Soc Hematol Educ Program. 2010;2010:108-14. doi: 10.1182/asheducation-2010.1.108. Hematology Am Soc Hematol Educ Program. 2010. PMID: 21239779 Review.
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD; Cancer and Leukemia Group B. Straus DJ, et al. Among authors: bartlett nl. Blood. 2011 May 19;117(20):5314-20. doi: 10.1182/blood-2010-10-314260. Epub 2011 Feb 25. Blood. 2011. PMID: 21355087 Free PMC article. Clinical Trial.
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Younes A, et al. Among authors: bartlett nl. J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454421 Free PMC article. Clinical Trial.
290 results